Biotechnology

Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

BioPharma Dive Dennis Kirkpatrick, DPR Construction

Making the ‘impossible’ executable in life sciences construction

Why early technical expertise matters when complex life sciences projects challenge convention.

Read at BioPharma Dive

BioPharma Dive

Translating Phase II success into Phase III readiness takes more than scale

The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.

Read at BioPharma Dive

The Rio Times Carlos Silva

Cuba and China Sign Three Biotech Deals

Cuba and China signed three biotechnology agreements in Shanghai on 6 November, a day after the US sanctioned two Chinese firms over military supplies to Cuba.

Read at The Rio Times

STAT Biotech Matthew Herper

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

Once again, a hot new technology that was supposed to speed up drug research has fallen flat.

Read at STAT Biotech

STAT Biotech John Wilkerson

STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries

The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.

Read at STAT Biotech

STAT Biotech Elizabeth Cooney and Matthew Herper

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

Read at STAT Biotech

STAT Biotech Elizabeth Cooney

STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories

“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: New tumor cases show common gene therapy tool can come with risk

New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.

Read at STAT Biotech

STAT Biotech Meghana Keshavan

STAT+: Amgen’s Repatha linked to fewer heart attacks

Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

Read at STAT Biotech

Green Queen (alternative protein) Anay Mridul

In A GLP-1 World, Danone Survey Finds Gut Health the Main Driver of Plant-Based Dairy

5 Mins ReadA major survey by French dairy giant Danone has revealed that health is the biggest driver of plant-based dairy consumption globally, with gut digestion a chief factor, spelling out an opportunity for fibre-enriched, GLP-1-friendly alternatives. The taste of oat milk matters less than how it feels to your gut, according to a new study by

Read at Green Queen (alternative protein)

STAT Biotech Ed Silverman and Jason Mast

STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy

Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

Read at STAT Biotech

STAT Biotech Meghana Keshavan and Jason Mast

STAT+: A possible comeback for a failed sickle cell gene therapy

Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…

Read at STAT Biotech

STAT Biotech Elizabeth Cooney

STAT+: Beyond statins, one drug lowered heart attack risk by 20%

A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."

Read at STAT Biotech

STAT Biotech Mario Aguilar

STAT+: Medicare delays controversial remote patient monitoring rule to 2029

Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.

Read at STAT Biotech

STAT Biotech Adam Feuerstein

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.

Read at STAT Biotech

STAT Biotech Jason Mast

STAT+: In China, a flood of controversial clinical trials slows to a trickle

Following patient deaths, China restricts investigator-initiated biotech trials, leaving rare disease families and US investors facing an uncertain future.

Read at STAT Biotech

STAT Biotech Margaret Manto

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

Sanders could use his role in crafting the FDA funding bill to push for reforms.

Read at STAT Biotech

STAT Biotech Elaine Chen

STAT+: Ultragenyx cuts staff after another study fails

Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.

Read at STAT Biotech

Tech in Asia Naomi Li Gan Startups

SG’s NeoSci Ventures secures $54.7m for first biotech fund

It plans to back up to 12 biotech companies globally.

Read at Tech in Asia

The Decoder Matthias Bastian SI

A Claude model autonomously chose a gene therapy and operated on a mouse brain with no human decision-making

An AI agent performed brain surgery on an epileptic mouse, picking the drug, the brain target, and the injection coordinates on its own. According to lead researcher Ocana-Santero, it's the first time an AI agent has autonomously chosen a treatment and delivered it to a living mammal. But when a calibration error hit mid-surgery, the agent refused to continue and couldn't be talked out of it. The article A Claude model autonomously chose a gene therapy and operated on a…

Read at The Decoder

MIT Technology Review Jessica Hamzelou

Eating disorders are on the rise. GLP-1s could make things worse.

GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that…

Read at MIT Technology Review

Asia Times Jeff Pao Geopolitics

Pre-APEC US ban on Chinese genomic giant widens biotech decoupling

Beijing has vowed to defend its firms after Washington blocked imports from China’s leading genomics group, extending the two countries’ trade war into biotechnology weeks before their leaders are due to meet in Shenzhen. The US Department of Homeland Security (DHS) on Wednesday added three Shenzhen-based companies to the Uyghur Forced Labor Prevention Act (UFLPA)

Read at Asia Times

Green Queen (alternative protein) Anay Mridul

Planet A Foods Unveils One-Ingredient Cocoa Powder Alternative to Cut Costs & Capture GLP-1 Market

6 Mins ReadGerman cocoa-free chocolate maker Planet A Foods has launched a single-ingredient Cocoa Booster powder to tackle rising costs and appeal to GLP-1 users via its high-fibre content. Planet A Foods, one of the leading startups in the alternative chocolate space, has its eye on the GLP-1 market with the rollout of Cocoa Booster, a one-ingredient

Read at Green Queen (alternative protein)

AgFunderNews Elaine Watson

iPROOF facility aims to bridge biotech’s valley of death

The iPROOF site in Decatur, IL, opens next May, and feature fermenters ranging from 1,200 to 10,000 liters alongside flexible DSP equipment.

Read at AgFunderNews

MIT Technology Review Thomas Macaulay

The Download: testing six tech promises and biotech’s blind spots

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Are we there yet? A reality check on six big tech promises Some seemingly impossible feats are too good to give up on. Decoding a pet’s yowls and yips? Absolutely. Scrubbing…

Read at MIT Technology Review

MIT Technology Review Jessica Hamzelou

In the biotech world, you can’t see everything

Earlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. I went in not really knowing what to expect. I’d avoided spoilers (and won’t be giving anything away here, either!). I was wondering what new information this film could reveal, given…

Read at MIT Technology Review

Green Queen (alternative protein) Anay Mridul

Herbalife & IIT Madras Launch Accelerator to Advance India’s Plant Biotechnology Sector

4 Mins ReadUS supplements giant Herbalife and the Indian Institute of Technology Madras have established a Phyto Innovation accelerator programme to translate plant biotechnology research into scalable solutions. Months after opening a plant cell fermentation centre, US dietary supplements corporation Herbalife and the Indian Institute of Technology (IIT) Madras are building on their collaboration with a new biotech

Read at Green Queen (alternative protein)